LDNscience® Awareness Campaign
Extend LDNscience’s success to new audiences
LDNscience – we did it! Now enable us to help the next 1 million patients!
LDNscience® has helped over 400,000 patients since its inception and has a mission to help educate doctors and patients about the benefits and use of Low Dose Naltrexone, (LDN) a *repurposed medication.
On March 1st, thanks to generous donors, we are launching our new redesigned LDNscience.org website.
We need your generous support to keep the momentum going and finance the following:
- a new animation video explaining how LDN works;
- a social media campaign focusing on the use of LDN for Crohn’s Disease, Multiple Sclerosis (MS) and Cancer;
- a forum for patients to share their experiences; and
- a Spanish-language website for LDNscience.org.
LDNscience® is a public information project of the MedInsight® Research Institute, a U.S.-based 501(c)(3) nonprofit working to bridge the ever-widening gap between medical research and actual medical practice. LDNscience® is dedicated to bringing relief to those who suffer from cancer and chronic medical conditions by raising awareness of:
- Commercially non-sponsored medications.
- Off-label or secondary uses for approved medications (drug-repurposing).
- Specialized tests that enable treatments to be tailored to the individual (Precision Medicine).
Clinical applications of LDN have made incredible inroads with Crohn’s disease, multiple sclerosis (MS), cancer and other serious diseases. LDN was first discovered by Dr. Ian S. Zagon and Dr. Patricia J. McLaughlin of Hershey Medical Center, Penn State University, and the first-ever clinical trial was carried out by Dr. Jill P. Smith of Hershey Medical Center, under the guidance of Moshe Rogosnitzky, founder of LDNscience.org.
* Drug repurposing is the application of known drugs and compounds for newly discovered uses.
A significant advantage of drug repurposing over traditional drug development is that since the repurposed drug has already passed all the toxicity and safety tests, its safety is already known thereby reducing the cost and time of development for much needed treatments.